Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno …

S Hendry, R Salgado, T Gevaert… - Advances in anatomic …, 2017 - journals.lww.com
Assessment of the immune response to tumors is growing in importance as the prognostic
implications of this response are increasingly recognized, and as immunotherapies are …

Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international …

S Hendry, R Salgado, T Gevaert… - Advances in anatomic …, 2017 - journals.lww.com
Assessment of tumor-infiltrating lymphocytes (TILs) in histopathologic specimens can
provide important prognostic information in diverse solid tumor types, and may also be of …

[HTML][HTML] A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer …

S Loibl, M Untch, N Burchardi, J Huober, BV Sinn… - Annals of …, 2019 - Elsevier
Background Combining immune-checkpoint inhibitors with chemotherapy yielded an
increased response rates in patients with metastatic triple-negative breast cancer (TNBC) …

Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer—the penelope-B trial

S Loibl, F Marmé, M Martin, M Untch… - Journal of clinical …, 2021 - ingentaconnect.com
PURPOSE About one third of patients with hormone receptor–positive, human epidermal
growth factor receptor 2–negative breast cancer who have residual invasive disease after …

Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an …

S Loibl, A Schneeweiss, JB Huober, M Braun, J Rey… - 2021 - ascopubs.org
506 Background: The GeparNuevo trial investigated the addition of durvalumab, an anti-PD-
L1 checkpoint inhibitor (CPI), to standard neoadjuvant chemotherapy (NACT) in patients …

[HTML][HTML] Quality of reporting of clinical non-inferiority and equivalence randomised trials-update and extension

P Schiller, N Burchardi, M Niestroj, M Kieser - Trials, 2012 - Springer
Background Non-inferiority and equivalence trials require tailored methodology and
therefore adequate conduct and reporting is an ambitious task. The aim of our review was to …

[HTML][HTML] Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry

I Witzel, E Laakmann, R Weide, T Neunhoeffer… - European Journal of …, 2018 - Elsevier
Abstract Background Brain metastases (BMs) have a major impact on life expectancy and
quality of life for many breast cancer patients. Knowledge about treatment patterns and …

Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative …

S Loibl, M Untch, N Burchardi, JB Huober, JU Blohmer… - 2018 - ascopubs.org
104 Background: Combining immune-checkpoint inhibitors with chemotherapy yielded high
response rates in patients (pts) with metastatic TNBC. Therefore, we evaluated the addition …

The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy—an open-label, prospective …

F Rosenow, C Schade-Brittinger… - Journal of Neurology …, 2012 - jnnp.bmj.com
Background Of the newer antiepileptic drugs, lamotrigine (LTG) and levetiracetam (LEV) are
popular first choice drugs for epilepsy. The authors compared these drugs with regard to …

Immune-related gene expression predicts response to neoadjuvant chemotherapy but not additional benefit from PD-L1 inhibition in women with early triple-negative …

BV Sinn, S Loibl, CA Hanusch, DM Zahm, HP Sinn… - Clinical cancer …, 2021 - AACR
Purpose: We evaluated mRNA signatures to predict response to neoadjuvant PD-L1
inhibition in combination with chemotherapy in early triple-negative breast cancer …